Selling Low T

Email ThisPrint ThisDeliciousDigg ThisGoogleShare to FacebookLinkedInRedditStumble ItShare to Twitter
Steven Woloshin and Lisa Schwartz

Steven Woloshin and Lisa Schwartz of The Dartmouth Institute for Health Policy & Clinical Practice (TDI) have analyzed the Low T marketing campaign. (Photo courtesy of TDI)

Read the full story, published by the Dartmouth Institute for Health Policy & Clinical Practice.

“We’re giving people hormones that we don’t know they need for a disease that we don’t know they have, and we don’t know if it’ll help them or harm them,” says Lisa Schwartz, a professor at the Dartmouth Institute for Health Policy & Clinical Practice, who wrote a 2013 paper about the marketing of low testosterone as a disease in need of a treatment.

This week, The New York Times, the Huffington Post, and NPR asked Schwartz to weigh in on the business of selling drugs for diseases that may not deserve the label “disease.”